Epidermal growth factor receptor T790M mutation as a prognostic factor in EGFR-mutant non-small cell lung cancer patients that acquired resistance to EGFR tyrosine kinase inhibitors

// Guangzhi Ma 1, 2, * , Jing Zhang 3, * , Hai Jiang 4, * , Nannan Zhang 3 , Liyuan Yin 1 , Wen Li 1 and Qinghua Zhou 1 1 Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P. R. China 2 Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China 3 Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China 4 Department of Orthopedic Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China * These authors contributed equally to this work Correspondence to: Qinghua Zhou, email: zhouqh135@163.com Keywords: NSCLC, T790M, EGFR-TKIs, prognosis, meta-analysis Received: March 13, 2017 Accepted: July 12, 2017 Published: July 29, 2017 ABSTRACT Epidermal growth factor receptor (EGFR) T790M mutation accounted for over half of drug resistance cases in EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs) and led to different outcomes. This study aimed to assess the prognostic role of T790M in NSCLC patients treated with EGFR-TKIs that developed drug resistance. Eligible literatures were reviewed from various databases and a meta-analysis was performed to evaluate the prognostic role of T790M mutation in EGFR-TKIs treated patients that went progression. Three studies containing 192 patients were included in the meta-analysis. The pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS) were 0.66 (95% CI 0.49–0.89, P = 0.007) and 0.53 (95% CI 0.35–0.79, P = 0.002) respectively. Subgroups analyses were also performed on OS and PFS according to patients’ districts, gender and histological type. In conclusion, T790M as a common mutation to cause drug-resistance in EGFR-TKIs treated NSCLC patients may be a favorable prognostic factor on OS and PFS both. Further studies are necessary to demonstrate the prognostic role of secondary T790M in NSCLC patients.